Does Personalized Vitamin D Titration Improve Outcomes After a Heart Attack?

"More vitamin D, better heart" is the kind of headline the nutraceutical industry has been printing for years — usually without a 25(OH)D number attached. The TARGET-D trial, now indexed in the European Heart Journal, finally drags that slogan into a randomized design and asks the only question that matters: does pushing post-myocardial infarction patients into a serum range of 40–80 ng/mL with personalized D3 titration actually move the major adverse cardiovascular events needle compared to usual care?

The design — and the threshold that actually matters

TARGET-D is pragmatic, not mechanistic. Enrollees were randomized to either standard care or a titration protocol that tracked 25(OH)D and escalated D3 dosing until participants landed inside the 40–80 ng/mL window. That range is not arbitrary: it sits well above the 20 ng/mL deficiency cutoff most reference labs still use, and it overlaps neatly with the "optimal" zone that high-dose advocates have been selling for over a decade. The endpoint is hard — MACE — not a surrogate lipid or inflammatory marker, not a self-reported wellness score. If the marketing claim "correct your D, save your heart" had a biochemical fingerprint, this is the trial designed to catch it in the act.

Adjacent signal: targeted dosing isn't only a cardiac story

Two other randomized reads landed within the same week, and they sharpen the picture. A Frontiers in Medicine prospective RCT in chronic liver disease reported that screening plus individualized D3 supplementation reduced non-invasive markers of liver fibrosis and hepatocellular injury. Separately, an European Journal of Clinical Nutrition trial in Indian children under five with nutritional rickets compared three daily D3 regimens for biochemical normalization and safety. Three different populations, three different endpoints, one consistent design logic: measure, dose to a target, reassess. The nutraceutical industry, by contrast, still defaults to "take 5,000 IU and hope."

The practical verdict — for now

Until the TARGET-D outcomes table is in hand, the defensible position for clinicians and policymakers is uncomfortable but honest: population-level fortification and deficiency correction remain the only moves supported by serum epidemiology and trial-grade evidence. Chasing a 40–80 ng/mL target in a post-MI patient is a hypothesis under test, not a protocol to import into a clinic — and certainly not a justification to fortify foods at supraphysiological doses. Watch the MACE result, watch the subgroup splits by baseline 25(OH)D, and resist any supplement brand that cites TARGET-D before the data are out.